Menu
Search Close

Using immunology to fight cancer

Read more

In Phase 1/2 clinical trials for the treatment of patients with metastatic melanoma

Read more

Novel vaccine platform that destroys tumours 

Read more

Cancer Immunotherapy

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The company, which was founded in 1997 as a spin-out from the University of Nottingham, has secured £23 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.

Read more

Presentation

Scancell Investor Presentation, February 16 2018

 

If you wish to see the full unedited version of this presentation please click here

Aim logo

Scancell Holdings PLC is an AIM listed company

Webcasts, Interviews and Media Coverage

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems

Wed, 18 Jul 2018 06:09:00

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform

Wed, 23 May 2018 05:28:00

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.

A placing and subscription at 12 pence a share will account for £6mln of the total.

The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.

Wed, 18 Apr 2018 12:18:00